JPRN-UMIN000019072
已完成
未知
The effect of luseogliflozin on epicardial fat accumulation in obese patients with type 2 diabetes - SGLT2 inhibitor and ectopic fat in T2DM
kyo Medical and Dental University0 个研究点目标入组 20 人开始时间: 2015年11月15日最近更新:
概览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- kyo Medical and Dental University
- 入组人数
- 20
概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who are taking SGLT2 inhibitors Patients with insulin treatment Patients with active infection, malignancy, severe liver or renal diseases Patients who are unable to figure out the consent due to dementia or impairment of consciousness Pregnant women, lactating woman, women who are planning to get pregnant Patients whose treatment for diabetes were changed 3 months prior to baseline evaluation
研究者
相似试验
已完成
不适用
The impact of Dapagliflozin on epicardial fat volumeType 2 DiabetesJPRN-UMIN000035660Tachikawa general hospital40
已完成
4 期
Dapagliflozin Effects on Epicardial FatType 2 DiabetesNCT02235298University of Miami100
已完成
4 期
Liraglutide Effects on Epicardial Fat Inflammatory GenesType2 DiabetesCoronary Artery DiseaseNCT03260881University of Miami40
已完成
3 期
Impact of Empaglifozine on Cardiac Ectopic FatType 2 DiabetesNCT03118336Assistance Publique Hopitaux De Marseille56
进行中（未招募）
1 期
Studying effects of medication (empagliflozin) in diabetes (or at risk of diabetes) and heart failureChronic heart failure with left ventricular systolic dysfunctionMedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003719-37-GBHS Greater Glasgow and Clyde100